Imatinib for refractory chronic graft-versus-host disease with fibrotic features

Copelan, 2006, Hematopoietic stem cell transplantation., N Engl J Med, 354, 1813, 10.1056/NEJMra052638 Ferrara, 2004, The pathophysiology of graft-vs.-host disease., Thomas' Hematopoietic Cell Transplantation, 3rd Ed, 353 Bell, 1996, Specificity of antinuclear antibodies in scleroderma-like chronic graft -versus-host disease: clinical correlation and histocompatibility locus antigen association., Br J Dermatol, 134, 848, 10.1111/j.1365-2133.1996.tb06314.x Koc, 2002, Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone., Blood, 100, 48, 10.1182/blood.V100.1.48 Arora, 2001, Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease., Biol Blood Marrow Transplant, 7, 265, 10.1053/bbmt.2001.v7.pm11400948 Kim, 2004, Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant., Eur J Haematol, 73, 56, 10.1111/j.1600-0609.2004.00247.x Flowers, 2008, A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease., Blood, 112, 2667, 10.1182/blood-2008-03-141481 Couriel, 2006, Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD., Blood, 107, 3074, 10.1182/blood-2005-09-3907 Cutler, 2006, Rituximab for steroid-refractory chronic graft-versus-host disease., Blood, 108, 756, 10.1182/blood-2006-01-0233 Socie, 1999, Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry., N Engl J Med, 341, 14, 10.1056/NEJM199907013410103 Svegliati, 2007, Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease., Blood, 110, 237, 10.1182/blood-2007-01-071043 Svegliati, 2006, Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis., N Engl J Med, 354, 2667, 10.1056/NEJMoa052955 Bonner, 2004, Regulation of PDGF and its receptors in fibrotic diseases., Cytokine Growth Factor Rev, 15, 255, 10.1016/j.cytogfr.2004.03.006 McCormick, 1999, Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma., J Immunol, 163, 5693, 10.4049/jimmunol.163.10.5693 Abdollahi, 2005, Inhibition of platelet-derived growth factor signalling attenuates pulmonary fibrosis., J Exp Med, 201, 925, 10.1084/jem.20041393 Daniels, 2004, Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin mediated lung fibrosis,, J Clin Invest, 114, 1308, 10.1172/JCI200419603 Distler, 2007, Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis., Arthritis Rheum, 56, 311, 10.1002/art.22314 Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia., N Engl J Med, 355, 2408, 10.1056/NEJMoa062867 Vitali, 2002, Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group., Ann Rheum Dis, 61, 554, 10.1136/ard.61.6.554 Couriel, 2006, Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease, V: Ancillary Therapy and Supportive Care Working Group Report., Biol Blood Marrow Transplant, 12, 375, 10.1016/j.bbmt.2006.02.003 Pavletic, 2006, Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, IV: Response Criteria Working Group report., Biol Blood Marrow Transplant, 12, 252, 10.1016/j.bbmt.2006.01.008 Clements, 1993, Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies., J Rheumatol, 20, 1892 Simon, 1989, Optimal two-stage designs for phase II clinical trials., Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Gooley, 1999, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators., Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O Martin, 2006, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, VI: Design of Clinical Trials Working Group report., Biol Blood Marrow Transplant, 12, 491, 10.1016/j.bbmt.2006.03.004 Antin, 2004, Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease., Biol Blood Marrow Transplant, 10, 655, 10.1016/j.bbmt.2004.07.007 Denton, 2007, Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192., Arthritis Rheum, 56, 323, 10.1002/art.22289 Johnston, 2005, Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease., Biol Blood Marrow Transplant, 11, 47, 10.1016/j.bbmt.2004.10.004 Jacobsohn, 2007, Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease., J Clin Oncol, 25, 4255, 10.1200/JCO.2007.10.8456 Cho, 2009, Feasibility of NIH consensus criteria for chronic graft-versus-host disease., Leukemia, 23, 78, 10.1038/leu.2008.276 Brennan, 1992, Reliability of skin involvement measures in SSc., Br J Rheumatol, 31, 457, 10.1093/rheumatology/31.7.457 Seggewiss, 2005, Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner., Blood, 105, 2473, 10.1182/blood-2004-07-2527